Profile Picture
Google ScholarScopusORCIDPublons
Organizational Units
Organizational Unit
Job Title
First Name
Last Name
Email Address
Birth Date

Search Results

Now showing 1 - 4 of 4
  • PublicationOpen Access
    Circulating furin, IL-6, and presepsin levels and disease severity in SARS-CoV-2-infected patients
    (2021-06-01T00:00:00Z) Kocyigit, Abdurrahim; Sogut, Ozgur; Kanimdan, Ebru; Guler, Eray Metin; Kaplan, Onur; Eren, Canan; Ozman, Zeynep; Yasar, Oznur; KOÇYİĞİT, ABDÜRRAHİM; BALKAN, EZGİ; KANIMDAN, EBRU; YENİGÜN, VILDAN BETÜL; ÖZMAN, ZEYNEP
    Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a vast number of infections and deaths that deeply affect the world. When the virus encounters the host cell, it binds to angiotensin-converting enzyme 2, then the S protein of the virus is broken down by the transmembrane protease serine 2 with the help of furin, allowing the virus to enter the cell. The elevated inflammatory cytokines suggest that a cytokine storm, also known as cytokine release syndrome, may play a major role in the pathology of COVID-19. Therefore, the aim of this study is to investigate the relationship between circulating furin levels, disease severity, and inflammation in patients with SARS-CoV-2. A total of 52 SARS-CoV-2 patients and 36 healthy control participants were included in this study. SARS- CoV-2 patients were scored by the disease activity score. Serum furin, presepsin, and interleukin-6 (IL-6) levels were assessed using an enzyme-linked immunosorbent assay. The mean furin, presepsin, and IL-6 levels were significantly higher in the peripheral blood of SARS-CoV-2 compared to the controls (p < 0.001). There were close positive relationship between serum furin and IL-6, furin and presepsin, and furin and disease severity (r = 0.793, p < 0001; r = 0.521, p < 0.001; and r = 0,533, p < 0.001, respectively) in patients with SARS-CoV-2. These results suggest that furin may contribute to the exacerbation of SARS-CoV-2 infection and increased inflammation, and could be used as a predictor of disease severity in COVID-19 patients.
  • PublicationMetadata only
    Regulation of valproic acid induced EMT by AKT/GSK3β/β-catenin signaling pathway in triple negative breast cancer
    (2021-01-30T00:00:00Z) Ozman, Zeynep; Ozbek Iptec, Betul; Sahin, Elvan; Guney Eskiler, Gamze; Deveci Ozkan, Asuman; Kaleli, Suleyman; ÖZMAN, ZEYNEP
  • PublicationMetadata only
    In vitro therapeutic effects of abemaciclib on triple-negative breast cancer cells.
    (2021-07-26T00:00:00Z) Ozman, Zeynep; Guney Eskiler, Gamze; Sekeroglu, Mehmet R; ÖZMAN, ZEYNEP
  • PublicationMetadata only
    IL-6 mediated JAK/STAT3 signaling pathway in cancer patients with cachexia
    (2019-01-01T00:00:00Z) Eskiler, Guney G.; Bezdegumeli, E.; Ozman, Zeynep; Ozkan, Deveci A.; Bilir, C.; Kucukakca, B. N.; Ince, M. N.; Men, A. Y.; Aktas, O.; Horoz, Y. E.; Akpinar, D.; Genc, I; Kaleli, S.; ÖZMAN, ZEYNEP
    OBJECTIVES: We investigated the changes in the IL-6 and STAT3 expression levels in cachectic and non-cachectic patients with gastric, lung and breast cancer and evaluated the association between IL-6 and STAT3 levels and cancer types in terms of cachexia condition. BACKGROUND: Cancer-associated cachexia, observed in nearly 50.80 % of cancer patients, has drawn attention in advanced patients. IL-6/JAK/STAT pathway plays an essential role in the progression of cancer cachexia through the regulation of the inflammatory response.